{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:27:17Z","timestamp":1790130437264,"version":"4.0.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"\n Importance<\/jats:title>\n Stereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy. Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). Current constraints designed to prevent RM after spine SBRT are derived from limited data.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize the risk of RM after spine SBRT and to update the dosimetric constraints for preventing it.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was conducted in a single tertiary cancer care center with patients treated for spinal metastases from 2014 to 2023. All included participants had undergone spine SBRT, had a minimum of 1-month follow-up with magnetic resonance imaging (MRI), a maximal cord dose to a voxel (Dmax) greater than 0 Gy, and no overlapping prior radiotherapy. In all, 2051 patients received SBRT to 2835 spinal metastases (levels C1-L2) during the study period.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Three-fraction spine SBRT to a prescription dose of 27 to 36 Gy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n RM defined as radiographic evidence of spinal cord injury in the treatment field, classified as grade (G) 1 to G4 or G3 to G4 per the Common Terminology Criteria for Adverse Events, version 5.0. Multiple dosimetric parameters of the true spinal cord structure were assessed for an association with risk of RM to determine the important covariates associated with this toxicity.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The analysis included 1423 patients (mean [SD] age, 61.6 [12.9] years; 695 [48.8%] females and 728 [51.1%] males) who received SBRT for 1904 spinal metastases. Among them, 30 cases of RM were identified, 19 of which were classified as G3 to G4. Two years after SBRT, the rate of G1 to G4 RM was 1.8% (95% CI, 1.2%-2.5%) and the rate of G3 to G4 RM was 1.1% (95% CI, 0.7%-1.7%). The minimum dose to the 0.1 cm\n 3<\/jats:sup>\n of spinal cord receiving the greatest dose (D0.1cc) was the most important covariate on univariable cause-specific hazards regression for RM (for G3 to G4: hazard ratio, 2.14; 95% CI, 1.68-2.72;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). A true cord D0.1cc of 19.1 Gy and Dmax of 20.8 Gy estimated a 1.0% risk (95% CI, 0.3%-1.6% and 0.4%-1.6%, respectively) of G3 to G4 RM 2 years after SBRT.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this cohort study indicate that a cord (myelogram or MRI-derived) D0.1cc constraint of 19.1 Gy and a Dmax constraint of 20.8 Gy correspond with a 1.0% risk of G3 to G4 RM at 2 years.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5387","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:01:55Z","timestamp":1734606115000},"page":"128","source":"Crossref","is-referenced-by-count":16,"title":["Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy"],"prefix":"10.1001","volume":"11","author":[{"given":"Christopher B.","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian A.","family":"Boe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Apte","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Haseltine","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Christopher","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Barzilai","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Bilsky","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lis","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Higginson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi240069r1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1634\/theoncologist.2012-0293","article-title":"The NOMS framework: approach to the treatment of spinal metastatic tumors.","volume":"18","author":"Laufer","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"coi240069r2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3171\/2015.11.SPINE151059","article-title":"Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study.","volume":"25","author":"Leeman","year":"2016","journal-title":"J Neurosurg Spine"},{"issue":"5","key":"coi240069r3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cncr.31870","article-title":"Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: a multicenter, international study.","volume":"125","author":"Barzilai","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"coi240069r4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/BRS.0b013e318223b9b6","article-title":"Clinical outcome of metastatic spinal cord compression treated with surgical excision \u00b1 radiation versus radiation therapy alone: a systematic review of literature.","volume":"37","author":"Kim","year":"2012","journal-title":"Spine (Phila Pa 1976)"},{"issue":"5","key":"coi240069r5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3171\/2015.8.SPINE15844","article-title":"Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I\/II trials.","volume":"24","author":"Ghia","year":"2016","journal-title":"J Neurosurg Spine"},{"issue":"22","key":"coi240069r6","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1200\/JCO.2010.28.5635","article-title":"Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression.","volume":"28","author":"Rades","year":"2010","journal-title":"J Clin Oncol"},{"key":"coi240069r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109969","article-title":"Efficacy and safety of SBRT for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline.","volume":"190","author":"Guninski","year":"2024","journal-title":"Radiother Oncol"},{"issue":"7","key":"coi240069r8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial.","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi240069r9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijrobp.2022.05.043","article-title":"Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy.","volume":"114","author":"Zeng","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi240069r10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","article-title":"Spinal cord dose tolerance to stereotactic body radiation therapy.","volume":"110","author":"Sahgal","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi240069r11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ijrobp.2012.05.007","article-title":"Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice.","volume":"85","author":"Sahgal","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"coi240069r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101047","article-title":"Single and multifraction spine stereotactic body radiation therapy and the risk of radiation induced myelopathy.","volume":"7","author":"Lucido","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"coi240069r13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijrobp.2010.01.040","article-title":"Tolerance of the spinal cord to stereotactic radiosurgery: insights from hemangioblastomas.","volume":"80","author":"Daly","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi240069r14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijrobp.2010.07.1979","article-title":"Spinal cord tolerance to single-fraction partial-volume irradiation: a swine model.","volume":"79","author":"Medin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi240069r15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1667\/RR3597.1","article-title":"Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival.","volume":"166","author":"Coderre","year":"2006","journal-title":"Radiat Res"},{"issue":"8","key":"coi240069r16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/sc.2015.43","article-title":"Pathobiology of radiation myelopathy and strategies to mitigate injury.","volume":"53","author":"Wong","year":"2015","journal-title":"Spinal Cord"},{"issue":"1","key":"coi240069r17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"issue":"3","key":"coi240069r19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3171\/2010.3.SPINE09459","article-title":"Reliability analysis of the epidural spinal cord compression scale.","volume":"13","author":"Bilsky","year":"2010","journal-title":"J Neurosurg Spine"},{"issue":"8","key":"coi240069r20","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101.","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"3","key":"coi240069r21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ijrobp.2017.05.053","article-title":"A detailed dosimetric analysis of spinal cord tolerance in high-dose spine radiosurgery.","volume":"99","author":"Katsoulakis","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi240069r22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.radonc.2006.11.023","article-title":"Image-guided robotic radiosurgery for spinal metastases.","volume":"82","author":"Gibbs","year":"2007","journal-title":"Radiother Oncol"},{"issue":"2","key":"coi240069r23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.semradonc.2015.11.010","article-title":"Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord.","volume":"26","author":"Grimm","year":"2016","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"coi240069r24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","article-title":"A systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and International Stereotactic Radiosurgery Society Recommendations.","volume":"118","author":"Vellayappan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi240069r25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11060-022-04037-0","article-title":"Radiation myelopathy following stereotactic body radiation therapy for spine metastases.","volume":"159","author":"Ong","year":"2022","journal-title":"J Neurooncol"},{"key":"coi240069r26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1130313","article-title":"Case series: immune checkpoint inhibitor-induced transverse myelitis.","volume":"14","author":"Chatterton","year":"2023","journal-title":"Front Neurol"},{"issue":"3","key":"coi240069r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101179","article-title":"Effect of immunotherapy and stereotactic body radiation therapy sequencing on local control and survival in patients with spine metastases.","volume":"8","author":"Eckstein","year":"2023","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"coi240069r28","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/j.ijrobp.2012.01.080","article-title":"Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery.","volume":"83","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi240069r18","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events. Accessed November 18, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2827893\/jamaoncology_jackson_2024_oi_240069_1739890042.8375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:02:16Z","timestamp":1740049336000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2827893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5387","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}